Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know - 2Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- 3Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
- 4The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- 5Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- My Pioneering Excursion: Building a Startup
- Volkswagen Just Revealed a Massive Range-Extended SUV for China, and America Isn’t Getting It
- 5 Chiefs That Changed Our Opinion on Film
- AstraZeneca to acquire Modella AI to speed oncology drug research
- Investigating Design and Individual Style: Track down Your Remarkable Look
- 2026 will be the year NASA astronauts fly around the moon again — if all goes to plan
- Holiday season sees uptick in norovirus cases, according to CDC
- What to know about King Charles III's cancer treatment and his message to the public
- Flu cases spiking this holiday season, CDC data shows
